Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013
Background Her2+ve patients 15% of all breast cancer Even with adjuvant trastuzumab 10-15% relapse Trastuzumab does not cross intact BBB High incidence of brain metastases Patients have a better prognosis
Management of Patients with Her2+ve Brain metastases Patients should be closely followed up Management depends on number & size of mets Important to control both systemic & brain disease Management of patients must be multidisciplinary Case studies
Presentation of Patients with Her2+ve Brain metastases Presentation at diagnosis with brain metastases +/- systemic disease No evidence of systemic disease and develop CNS disease (only) in follow up On treatment for systemic metastases and develop brain metastases with systemic disease either controlled or progressing
Classification of patient Number of metastases Size of metastases Location within brain Control of extracranial disease
Understand Prognosis
Priestman TJ et al. Final results of the RCR trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. Clin Oncol 1996,8:308 315 533 patients were eligible for analysis: Median survival was 77 days with two fractions (95% CI 68-89) and 84 days for the longer schedule (95% CI 67-102). overall responses were seen in 39% of those given two fractions and 44% of patients receiving ten fractions.
RPA RTOG RPA scores (recursive partitioning analysis) Class Definition Median Survival controlled primary RPA 1 age<65 no extracranial mets 7.1 months RPA 2 neither RPA 1 or RPA 3 4.2 months RPA 3 KPS<70 2.3 months RED 1997;37:745-751 RED 2008;70:510-514
Proportion surviving Overall survival by independent assessment Median OS, mos No. events Hazard ratio 95% CI Log-rank P value 1.0 lap + Xeloda (n=70) Kadcyla (n=67) 25.1 182 30.9 149 0.682 0.55 0.85 P<0.001 85.2% 0.8 0.6 78.4% 64.7% 0.4 51.8% 0.2 No. at risk lap+ Xeloda Kadcyla 0 Time (months) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 496 495 471 485 453 474 435 457 403 439 368 418 297 349 240 293 204 204 159 197 133 164 110 136 86 111 63 86 45 62 27 38 17 28 7 13 4 5
Breast GPA graded prognostic assessment Basal ER - Her 2 - Luminal A ER + Her 2- Her2 ER - Her2 + Luminal B ER + Her2 + Sperduto Red Journal 2012 82(5)
Multiple Brain Metastases
Isolated brain metastases Post whole brain radiotherapy Good response Poor response Observe closely Consider xeloda Monitor need for Radiosurgery
The blood brain barrier EGF100151 1 showed a lower incidence of 1st progression at CNS sites in the lap+cap arm 2 Exploratory results from EAP. lap+cap demonstrated an overall response rate of 18% in the CNS 3. In EGF105084, 241 patients were given lapatinib only. The CNS response rate was 6% (16/241). Addition of capecitabine to lapatinib in 49 patients with CNS disease progression on lapatinib alone. CNS responses occurred in 20% 4. 1. Geyer CE et al. NEJM 2006;355: 2733-2743. 2.Cameron D, et al. Breast Cancer Res Treat 2008; 112: 533 543. 3. Boccardo et al.. JCO 2008; 26: 64s (Abstr 1094). 4.Lin NU, et al..j Clin Oncol (Meeting Abstracts) 2007; 25: 35s (Abstr 1012).
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: RCT Hopkins Verbal Learning Test used to measure decline in learning and memory The primary endpoint was cognitive decline in learning and memory. Pts randomized to SRS+WBRT had twice the risk of cognitive decline compared to SRS pts (52% versus 24%). 73% of patients in the SRS plus WBRT group were free from CNS recurrence at 1 year, compared with 27% of patients who received SRS alone Trial stopped by data monitoring committee because of excess memory decline Chang EL. Lancet Oncol 2009;10(11):1037-44
WBRT - Side effects and concerns Neurological QOL /SE not just due to WBRT Systemic therapy e.g. chemo Previous surgery Drugs e.g. Steroids Anticonvulsants Opioids Systemic disease Review of effects of WBRT 1 Neurocognitive decline maximal at 4 months Insufficiently assessed in long term survivors Partially resolves over time Generally not severe Dependent on brain metastases control 1. Neurocognitive function impairment after WBRT for brain mets:, Radiation Oncology 2012, 7:77
Oligometastases
Alternative local treatment for 1-3 mets Stereotactic Radiotherapy Gammaknife Cyberknife Linac based NCB draft guidance all platforms are acceptable (need centre to be competent at delivery of these techniques)
NEED MDT SRS/SBRT Boost after WBRT RTOG 9508 (Lancet 2004;363:1665-1672) SRS instead of WBRT (Aoyama JAMA 2006;295:2483-91) Most now feel SRS and surgery are equal Surgery better for some & SRS for others Attraction: avoid WBRT side effects
NHSCB/D5/1 guidance on SRS/SRBT MDT; local, neuro, stereotactic PS KPS>70 Diagnosis of cancer established and absent or controllable primary disease No pressure symptoms (or surgery) Pre treatment scans vol <20cc (<3cm)** Life expectancy from extracranial disease >6months Treat new lesions - >3months and above Retreat lesions - >6 months and above
EORTC 22952-26001 JCO 2011 29(2) 134-41 Phase 3 to define role of adj WBRT after local therapy (surgery or RS) Hypothesis: WBRT can increase duration of functional independence Stable systemic CA 1-3 brain mets <3cm WHO PS 0-2 Randomize WBRT vs Observation 1 o survival with independence measured by time to WHO PS >2 2 o intracranial relapse, PFS, OS, late toxicity and QOL Breast cancer 11% of the 359 pts entered (?HER2)
QOL Results Not dedicated neurocog function but use QOL (EORTC QLQ-C30 and QLQ BN20) Overall, pts better QOL in observation arm Stat significant for; global health at 9 months Physical functioning at 8 wks Cognitive function at 12 months Fatigue at 8 wks Conclusion WBRT has negative impact therefore observation with close MRI FU better approach JCO 2013 31(1) 65-72
WBRT Observation PFS (Months) 4.6 3.4 Neurol Death (%) 28 44 Initial lesion 2yr RR after surgery (%) 27 59 Initial lesion 2yr RR after radiosurgery (%) 19 31 New site 2yr RR after surgery (%) 23 42 New site 2yr RR after radiosurgery (%) 33 48 Time to PS>2 (months) 9.5 10 Death Intracranial progression (%) 28 44 Median OS (months) 10.9 10.7 70% randomised to observation avoided WBRT completely Salvage therapy more frequent in the observation arm
Neurocognitive Sparing Strategies Use memantine to prevent radiation damage Hippocampal shielding techniques for WBRT Irradiate surgical tumour beds with radiosurgery Use low dose per fraction 40Gy in 20 fractions?
CASES
Case presentation 1 LR 31.1.63 42 at diagnosis. CA Lt Brst. Lt WLE +ANC June 2005 T1(18) N0 G3 ER+ HER2+ Nov10: Liver lung Ophthalmic and Bone mets. Feb 12 : Brain mets-widespread. Given WBRT Apr 12: 4cm mediastinal mass. Pamidronate xeloda lapatinib.
Case presentation 1 Aug 12: Scanning PR mediastinum and brain. Oct 12: Chemo break due to side effects Feb 13: Progressive liver mets. Stable brain mets. TDM-1 trial Oct 13: CR liver and excellent PR brain.
13/2/12 diagnosis 14/4/12 post WBRT 14/8/12 4/12 X+L 1/10/12 Chemo break 18/2/13 Start TDM-1
Feb 2013 Oct 2013
Case presentation 2 KS 17.6.77 33 at diagnosis CA Rt Brst. Masty +ANC Nov 2010 T2 N3 G3 ER+ HER2+ Apr 12: Headaches oligomets. No visceral mets. Excision Rt cerebellar met. WBRT 30Gy/10fractions-PR Options gamma knife or alternative systemic therapy. Xel + lap given to shrink mets. Sept 12 PR. Nov 12: increased Lt frontal & parietal lesions. Gamma knife
4/4/12 23/5/12 28/8/12 21/11/12 4/2/13 diagnosis Post WBRT 3/12 X+L 6/12 X+L Post ɣ knife
Case presentation 2 April 13 progression left frontal lobe metastasis & new right cerebellar lesion Excision left frontal metastasis May 2013 Gamma knife cerebellar lesion June 2013 MRI Sept 2013 no progression. No visceral mets.
4/2/13 Post ɣ knife 23/4/13 progression 12/9/13 post excision & ɣ knife
Summary Concern of systemic control vs. other solid tumours Prognosis of Her2+ve brain mets Management of brain mets requires MDT approach Surgery SRS WBRT & Chemotherapy all have a role
Optimal Management of Isolated HER2+ve Brain Metastases Eliot Sims November 2013